Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 4, 2008, Pages 438-445

  Wacker, D A ^a   Miller, K J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Lorcaserin; Obesity; Schizophrenia; Serotonin; Vabicaserin

Indexed keywords

2,7 DIAZABICYCLO[3.3.0]OCTANE; APD 356; ATHX 105; AZEPINE DERIVATIVE; BVT 933; CP 809101; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LORCASERIN; PIPERAZINE DERIVATIVE; PLACEBO; PYRROLE DERIVATIVE; SCA 136; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; VABICASERIN; WAY 163909; WAY 16909;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE MODEL; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; NAUSEA; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SCHIZOPHRENIA; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; MOOD DISORDERS; OBESITY; OCULAR HYPERTENSION; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 46749140230     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 2C receptor agonists: Potential for the treatment of obesity. Mol Interv (2005) 5(5):282-291.
2. 2C agonist was applicable in several disease indications.
3. 2) receptor-mediated signal transduction in human ciliary muscle: Role in ocular hypotension. J Ocul Pharmacol Ther (2006) 22(6):389-401.
4. 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab (2008) 6(5):398-405.
5. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev (1994) 46(2):157-203.
6. 2C): Where structure meets function. Pharmacol Ther (1998) 79(3):231-257.
7. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol (2000) 57(1):75-81.
8. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102(23):2836-2841.
9. 1C receptor mRNA in adult rat brain. FEBS Lett (1989) 247(2):453-462.
10. 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology (1995) 34(12):1635-1645.
11. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB: Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 387(6630):303-308.
12. 2C receptor. Neuropsychopharmacology (1999) 21(2 Suppl):82S-90S.
13. 2C serotonin receptors. Nature (1995) 374(6522):542-546.
14. 2C receptor gene. Nat Med (1998) 4(10): 1152-1156.
15. 2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (2000) 152(3):256-267.
16. 2C receptor agonists for obesity. 229th American Chemical Society National Meeting, San Diego, CA, USA (2005):MEDI 283.
17. 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther (2005) 313(2):862-869.
18. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE et al: Activation of central melanocortin pathways by fenfluramine. Science (2002) 297(5581):609-611.
19. 2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat pre-frontal cortex. J Neurochem (2002) 82(1):93-100.
20. 2C/2B receptor agonists: A combined in vivo electrophysiological and microdialysis study. Synapse (2000) 35(1):53-61.
21. Sharif NA, McLaughlin MA, Kelly CR: AL-34662: A potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J Ocul Pharmacol Ther (2006) 23(1):1-13.
22. Tobin AB, Unger W, Osborne NN: Evidence for presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J Neurosci (1988) 8(10):3713-3721.
23. Biovitrum AB: Biovitrum completes successful phase IIa trial for anti-obesity treatment. Press Release (2002) February 27.
24. 2C receptor agonists. Press Release (2003) May 22.
25. Arena Pharmaceuticals Inc: Arena Pharmaceuticals initiates clinical trial of novel anti-obesity drug. Press Release (2004) February 24.
26. 2C receptor agonist for the treatment of obesity. J Med Chem (2008) 51(2):305-313. • Highlights the discovery of lorcaserin, which is currently in phase III clinical trials for the treatment of obesity.
27. Arena Pharmaceuticals Inc: Arena Pharmaceuticals initiates phase 1b clinical trial of novel anti-obesity drug. Press Release (2004) July 26.
28. Arena Pharmaceuticals Inc: Arena Pharmaceuticals announces results of its phase 1b safety study for its novel anti-obesity compound. Press Release (2004) November 30.
29. Arena Pharmaceuticals Inc: Arena Pharmaceuticals initiates phase 2 efficacy study for its novel anti-obesity compound. Press Release (2004) December 22.
30. Arena Pharmaceuticals Inc: Arena Pharmaceuticals announces positive phase 2b clinical trial results of novel anti-obesity compound. Press Release (2005) December 13.
31. 2C agonist for weight management. The Obesity Society 2007 Annual Scientific Meeting, New Orleans, LA, USA (2007).
32. Arena Pharmaceuticals Inc: Arena Pharmaceuticals initiates lorcaserin phase 3 obesity clinical trial. Press Release (2006) September 12.
33. Arena Pharmaceuticals Inc: Arena Pharmaceuticals initiates second and third pivotal trials evaluating lorcaserin for the treatment of obesity. Press Release (2007) December 13.
34. Wyeth: Drug development pipeline: SCA-136, SAX-187, PAI-749, SSA-426, PAI-749, GPG-290 and GAP-486. Thomson Pharma - Company Communication (2004) May 11.
35. Product Listing: Wyeth, Madison, NJ, USA (2008). www.wyeth.com/research/projects
36. 2C agonist, for the treatment of schizophrenia. 231st American Chemical Society National Meeting, Atlanta, GA, USA (2006):MEDI 021.
37. 2C receptor selective agonist. Abstr Soc Neurosci (2006):93.5.
38. 2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. Abstr Soc Neurosci (2006):93.4.
39. 2C agonist SCA-136. Abstr Soc Neurosci (2006):529.24.
40. Clinical Trial Listings: Schizophrenia: Wyeth, Madison, NJ, USA (2008). www.wyeth.com/ClinicalTrialListings?query=Schizophrenia
41. Athersys Inc: Athersys begins phase I trial for ATHX-105 for treatment of obesity. Press Release (2007) July 25.
42. ATHX-105 for Obesity: Athersys Inc, Cleveland, OH, USA (2008). www.athersys.com/Home/productCandidates/ATHX105forObesity/tabid/70/Default. aspx
43. 2C) receptor. Curr Top Med Chem (2006) 6(18):1927-1970.
44. 2C agonists for obesity.
45. 2C agonists in treating obesity. Expert Opin Investig Drugs (2006) 15(3):257-266.
46. 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther (2007) 320(1):486-496.
47. 2C receptor agonist WAY-163909 in rodents. Psychopharmacology (2007) 192(2):159-170.
48. 2C receptor agonists. Bioorg Med Chem Lett (2006) 16(11):2891- 2894.
49. 2C receptor agonist. Bioorg Med Chem Lett (2006) 16(15):4130-4134.
50. 2C receptor. J Med Chem (2007) 50(6):1365-1379.
51. 2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology (2007) 52(2):279- 290.
52. 2C receptor agonist for the treatment of obesity: Role of metabolic activation. Drug Metab Dispos (2007) 35(6):848-858.
53. 2 receptor agonist with ocular hypotensive activity. J Med Chem (2006) 49(1):318-328.
54. 2C agonists in ocular hypertension. References to patent literature
55. 2C agonists. WO-2005044812 (2005).
56. WYETH (Stack GP, Huselton CA, Wang J, Demaio W, Jordan R, Erve JCL, Talaat RE, Hoffmann MJ): Dihydrobenzofuran derivatives and uses thereof. WO-2006116150 (2006).
57. 2C agonists. WO-2006116151 (2006).
58. WYETH (Zhou D, Stack GP, Gross JL, Gao H): Benzodioxane and benzodioxolane derivatives and uses thereof. WO-2006116158 (2006).
59. ATHERSYS INC (Bennani YL, Huck B, Robarge MJ, Bom DC, Varga N, Tumey LN): Substituted azepine derivatives as serotonin receptor modulators. WO-2006004931 (2006).
60. 2C receptor ligands and uses thereof. WO-2007084622 (2007).
61. ATHERSYS INC (Bennani YL, Bom DC, Robarge MJ): Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators. WO-2006028961 (2006).
62. ATHERSYS INC (Bennani YL, Huck B, Robarge MJ): Tricyclic indenopyrrole derivatives as serotonin receptor modulators. WO-2007081299 (2007).
63. PFIZER PRODUCTS INC (Chen H, Coffey SB, Lefker BA, Liu K-C): Cyclopentylpyridine and tetrahydroquinoline derivatives. WO-2006103511 (2006).
64. PFIZER PRODUCTS INC (Liu K-C, Zeng Y): Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyloxy]-2- [(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine. WO-2008010073 (2008).
65. FOREST LABORATORIES INC (Araldi G-L, Bischoff A, Diep NK): Pyridoazepine derivatives. WO-2007140213 (2007).
66. 2C ligands. WO-2008009125 (2008).
67. ALCON MANUFACTURING LTD (Mohapatra S, Hellberg MR, Feng Z): Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma. US-20070293475 (2007).
68. ALCON INC (Hellberg MR, Namil A, Feng Z, Ward J): Phenylethylamine analogs and their use for treating glaucoma. WO-2007038372 (2007).